The FDA has a new warning about GLP-1s and vision loss. Should you worry?

Key Points:

• Sen. John Cornyn (R-Texas) is retiring after over 20 years in the Senate and has met with his Democratic successor, James Talarico, to assist with the office transition; Cornyn remains confident he could have retained the seat if on the ballot.
• Nvidia has hired former federal prosecutor Joon H. Kim to investigate CEO Jensen Huang’s affair with an alleged Chinese spy, amid concerns about potential national security risks linked to the company’s AI chip technology.
• Cranbury Township, New Jersey, officials defended delaying public disclosure of a $26 million theft from a bond issuance until after elections, citing law enforcement advice to avoid compromising the ongoing investigation, which has recovered about $17.5 million so far.
• The Pan American Health Organization is reviewing whether the US has lost its measles elimination status due to continuous transmission exceeding 12 months, following a surge in cases and outbreaks since early 2025.
• A nor’easter is expected to bring the season’s first snow to mountainous areas of the Northeast later this week, accompanied by chilly rain and blustery winds, followed by a significant cold snap across the eastern US this weekend.
• The FDA now requires GLP-1 medication labels to warn of a potential, though very rare, increased risk of vision loss from non-arteritic anterior ischemic optic neuropathy (NAION); experts advise patients to discuss risks with doctors but emphasize the overall health benefits of these drugs.